sequanamedical

Commercial stage medical device company developing the **alfa**pump® platform for the management of fluid overload in liver disease, malignant ascites and heart failure.

Fast facts

- Founded in 2006
- Headquarters in Ghent, Belgium
- Manufacturing in Zurich, Switzerland
- ~45 employees
- Listed on Euronext Brussels: SEQUA
- Unique **alfa**pump® platform
- Strong IP position
- Global network of KOLs in Europe and North America

Sequana Medical's **alfa**pump is a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is urinated away.

In the US, the company's key growth market, the **alfa**pump has been granted breakthrough device designation by the FDA. The North-American pivotal POSEIDON study has started in H2 2019 in patients with recurrent or refractory ascites due to liver cirrhosis, with US approval expected in H1 2022.

In the EU, the **alfa**pump is CE-marked for the treatment of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 750 **alfa**pump devices have been implanted to date.

alfapump DSR (Direct Sodium Removal) is in clinical development for treatment of fluid overload due to heart failure. Clinical proof-of-concept of single dose DSR therapy was achieved and a repeated dose **alfa**pump DSR study started in H2 2019, with results expected in Q2 and Q3 2020.

Focus on NASH[1] and heart failure, large and growing markets driven by unhealthy lifestyles, obesity and an ageing population

NASH in US

~145k patients / year with refractory ascites due to NASH within next 10-20y[2]

Heart failure in EU & US

~400 K patients hospitalised / year for volume overload due to heart failure by 2026[3]



NASH:

Fluid overload is a fast-growing complication of advanced liver disease driven by NASH (non-alcoholic steatohepatitis) related cirrhosis which is forecast to grow dramatically, in particular in the US.

Heart Failure:

Volume overload is a major clinical complication of heart failure and 40% of heart failure patients on IV loop diuretics are poorly controlled with diuretics.[4]

alfapump®: using the bladder to manage fluid overload

Fully-implanted, wirelessly-charged, CE-marked system that automatically and continuously pumps fluid from the abdominal cavity into the bladder, where the body eliminates the fluid naturally.



1. Automatic and continuous removal of fluid from the abdomen
2. Fluid is pumped into bladder
3. Fluid leaves the body through normal urination
4. Wireless charging and communication for monitoring

alfapump DSR: potential chronic therapy for heart failure patients not well controlled on diuretics

DSR therapy focuses on the removal of excess sodium from the body, and allows the body to naturally remove the excess fluid via urination and osmotic ultrafiltration.

alfapump DSR builds on the proven **alfa**pump and is in development to deliver a fully implanted and automated system for DSR therapy.



alfapump and alfapump DSR: near-term value drivers

North America Liver (NASH)

- Pivotal **alfa**pump study (POSEIDON) started H2 2019 with interim results expected H2 2020 and primary outcome readout mid-2021

Heart Failure

- Repeated dose **alfa**pump DSR study (RED DESERT) started H2 2019 with results expected Q2 and Q3 2020

Europe Liver & Cancer

- **alfa**pump study in malignant ascites & **alfa**pump registry in liver
- Focused commercial expansion of **alfa**pump in UK, Germany, Switzerland & France

For more information, visit www.sequanamedical.com or contact IR@sequanamedical.com

Sources
1: Non-alcoholic steatohepatitis
2: Management estimate based on GlobalData Epidemiology Forecast to 2026
3: Management estimate based on GlobalData Epidemiology Forecast to 2026; Constanzo et al. (2007). Kiglore et al (2017)
4 : Testani, Circ Heart Failure, 2014 & 2016

Important Regulatory Disclaimer: *The **alfa**pump has not yet received regulatory approval in the US and Canada. DSR therapy and **alfa**pump DSR are still in development and there is no link between DSR therapy, **alfa**pump DSR and ongoing investigations with the alfapump system in Europe, the US and Canada.*

Timings presented on this document are likely to be delayed given the COVID-19 global health crisis. Updated guidance will be provided when the situation is clarified.